Of the 15 subjects enrolled into the first stage, seven (46.7%) required dose reductions for ruxolitinib, primarily due to anemia, a known on-target (JAK2) toxicity, including 3 (20%) that required two dose reductions (20 mg followed by 15 mg). The gene discussed is JAK2; the disease is anemia.